Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Volitionrx (VNRX) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Volitionrx (VNRX) over the last 9 years, with Q2 2025 value amounting to $330.0.

  • Volitionrx's Other Operating Expenses rose 10098.51% to $330.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $917591.0, marking a year-over-year decrease of 4398.6%. This contributed to the annual value of -$34731.0 for FY2024, which is 11921.98% down from last year.
  • Per Volitionrx's latest filing, its Other Operating Expenses stood at $330.0 for Q2 2025, which was up 10098.51% from $917299.0 recorded in Q1 2025.
  • Volitionrx's Other Operating Expenses' 5-year high stood at $1.8 million during Q4 2021, with a 5-year trough of -$33498.0 in Q2 2024.
  • Over the past 5 years, Volitionrx's median Other Operating Expenses value was $561913.0 (recorded in 2021), while the average stood at $749107.7.
  • As far as peak fluctuations go, Volitionrx's Other Operating Expenses soared by 43603.84% in 2021, and later crashed by 15428.57% in 2024.
  • Quarter analysis of 5 years shows Volitionrx's Other Operating Expenses stood at $1.8 million in 2021, then dropped by 2.38% to $1.8 million in 2022, then plummeted by 100.0% to $70.0 in 2023, then tumbled by 154.29% to -$38.0 in 2024, then skyrocketed by 968.42% to $330.0 in 2025.
  • Its last three reported values are $330.0 in Q2 2025, $917299.0 for Q1 2025, and -$38.0 during Q4 2024.